KELYNIAM GLOBAL INC - KLYG STOCK NEWS

Kelyniam Global (OTC:KLYG) announced its Q1 2022 results, revealing total revenue of $656,858, down 0.1% from $664,353 in Q1 2021. The gross margin slightly improved to $509,201 from $505,326, while operating income showed a loss of $5,924 compared to a profit of $13,806 a year earlier. CEO Ross Bjella noted that revenue figures were influenced by previous COVID-related demand, and he anticipates growth from the launch of CustomizedBone. The company is enhancing its sales team to target new contracts.

Kelyniam Global (OTC: KLYG) reported a record year in 2021, showcasing a 6.06% increase in total revenue to $2,664,434 and a remarkable 363.2% surge in operating income to $180,445. Net income rose by 43% to $201,741. The company announced a new strategic partnership with Fin-ceramica and received a patent for its Integrated Fixation System, enhancing its product offerings and intellectual property. Despite operational challenges from COVID-19, Kelyniam remains committed to growth and quality improvements, with the hiring of a new VP in Quality and Regulatory Affairs.

Kelyniam Global, Inc. (OTC: KLYG) announced a strategic licensing agreement with Fin-ceramica faenza spa to market a hydroxyapatite cranial implant. This product utilizes a bio-mimetic ceramic biomaterial, mainly consisting of hydroxyapatite, which enhances osteointegration and reduces post-operative infections compared to titanium implants. The CustomizedBone Service™ implant will be distributed by Kelyniam's salesforce of over 50 representatives starting in January. This partnership aligns with both companies' focus on innovative, patient-centered technology.

Kelyniam Global has received a US patent for its Integrated Fixation Tabs, enhancing its custom cranial implant offerings. The patent, filed in 2014 and valid until 2037, covers the inclusion of fixation appendages, potentially reducing surgical costs and time by eliminating the need for plates and screws. CEO Ross Bjella emphasizes that this innovation underscores Kelyniam's commitment to advancing medical technology. The company collaborates closely with surgeons to optimize implant placement, which can result in better cosmetic outcomes for patients.

Kelyniam Global (OTC:KLYG) reported third-quarter results for the period ended September 30, 2021. Despite a 0.9% revenue decline year-over-year to $1,953,267, the company experienced strong quarterly sales growth that offset earlier pandemic-related delays. Gross margin increased to $1,494,067, and net income rose to $222,353 compared to $117,651 last year. The company’s shares were upgraded to ‘Pink Current’ status on November 5, enhancing trading liquidity. Additionally, a $144,000 Paycheck Protection Plan loan was forgiven, benefiting the financials.

Kelyniam Global (OTC: KLYG) has submitted all documentation to establish itself as a 'Pink Current' filer ahead of the September 30, 2021 deadline. This move reflects the company's commitment to transparency for its shareholders. Until the review is complete, Kelyniam will remain a 'Pink Limited' filer but will continue to have its stock actively traded. The company also reported advancements regarding its Integrated Fixation System (IFS) patent and a positive acknowledgment from the FDA concerning its remediation plan on earlier observations.

Kelyniam Global (OTC:KLYG) reported financial results for the first half of 2021, showing a revenue decline of 3.25% to $1,224,059 compared to $1,265,235 in 2019. Operating income fell significantly from $181,395 to $47,167, with net income dropping from $184,567 to $5,544. Delays from the Covid-19 pandemic affected surgery schedules, impacting revenue generation. Kelyniam announced that $144,000 of its Paycheck Protection Plan loan will be forgiven, affecting the 3rd quarter's accounting. The company is also addressing FDA audit findings amid supply chain delays.

Kelyniam Global (KLYG) reported its Q1 financial results for the period ending March 31, 2021, showcasing a 13.4% increase in total revenue to $664,353 compared to $585,786 in Q1 2020. Despite challenges from the pandemic, the company maintained profitability with a gross margin of $505,326. However, operating income fell to $13,806 from $68,315 in the previous year. Kelyniam aims to capture market opportunities as elective surgeries resume and plans to focus on increasing market share and supporting growth through infrastructure investments.

Kelyniam Global (OTC:KLYG) reported a return to profitability for the year ended December 31, 2020, marking a significant milestone in its five-year plan. Total revenue rose by 15.1% to $2,512,101, with gross margin increasing to $1,183,651. The company achieved an operating income of $157,309 and net income of $168,753, rebounding from prior losses. The success is attributed to effective expense management and sales growth, despite challenges from elective surgery restrictions due to COVID-19. Kelyniam's leadership remains optimistic about performance in 2021 as the economy gradually reopens.